Science Explorer Back to mapMap
Discussion
Company · Cambridge · United States

Mersana Therapeutics (United States)

Research works
66
▼ 20% vs 2018-21
Citations
1.1k
16.0 per fractional work
Top-10% rate
21.1%
all institutions 10.0%
Open access
27%
world 40%
International
8%
world 18%

Not ranked overall: Mersana Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Mersana Therapeutics (United States) work in?

In all years, 68% of research at Mersana Therapeutics (United States) is in Health Sciences, 26% in Life Sciences. Its largest fields are Medicine (68%), Biochemistry, Genetics and Molecular Biology (19%), Immunology and Microbiology (7%). It does 2.6× the world's share of Health Sciences.

Health Sciences: 45 fractional works · 67.8% of its workMedicine: 45 fractional works · 67.6% of its workOncology: 22 fractional works · 33.1% of its workRadiology, Nuclear Medicine and Imaging: 16 fractional works · 24.8% of its workPulmonary and Respiratory Medicine: 2 fractional works · 3.1% of its workNeurology: 1 fractional works · 1.9% of its workReproductive Medicine: 1 fractional works · 1.4% of its workSurgery: 1 fractional works · 0.8% of its workHematology: 0 fractional works · 0.5% of its workPharmacology: 0 fractional works · 0.5% of its workEpidemiology: 0 fractional works · 0.4% of its workGenetics: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.6% of its workHealth Professions: 0 fractional works · 0.2% of its workVeterinary: 0 fractional works · 0.1% of its workLife Sciences: 17 fractional works · 26.0% of its workBiochemistry, Genetics and Molecular Biology: 12 fractional works · 18.8% of its workMolecular Biology: 7 fractional works · 10.6% of its workBiotechnology: 2 fractional works · 3.8% of its workGenetics: 1 fractional works · 1.7% of its workCancer Research: 1 fractional works · 1.3% of its workCell Biology: 1 fractional works · 0.8% of its workMolecular Medicine: 0 fractional works · 0.5% of its workImmunology and Microbiology: 5 fractional works · 7.1% of its workImmunology: 4 fractional works · 6.6% of its workApplied Microbiology and Biotechnology: 0 fractional works · 0.5% of its workSmaller subfields together: 0 fractional works · 0.0% of its workNeuroscience: 0 fractional works · 0.1% of its workPhysical Sciences: 4 fractional works · 6.2% of its workEngineering: 1 fractional works · 2.2% of its workBiomedical Engineering: 1 fractional works · 1.7% of its workElectrical and Electronic Engineering: 0 fractional works · 0.5% of its workChemistry: 1 fractional works · 2.2% of its workOrganic Chemistry: 1 fractional works · 2.2% of its workComputer Science: 1 fractional works · 1.0% of its workComputational Theory and Mathematics: 1 fractional works · 1.0% of its workMaterials Science: 0 fractional works · 0.7% of its workBiomaterials: 0 fractional works · 0.7% of its workEnvironmental Science: 0 fractional works · 0.2% of its workPhysics and Astronomy: 0 fractional works · 0.0% of its workALL ITS WORKMersanaTherapeutics…66fractional works, all years
Life Sciences26%Physical Sciences6%Health Sciences68%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 12 fields, with their numbers
    1. Medicine4567.6%
    2. Health Professions00.2%
    3. Veterinary00.1%
    1. Biochemistry, Genetics and Molecular Biology1218.8%
    2. Immunology and Microbiology57.1%
    3. Neuroscience00.1%
    1. Engineering12.2%
    2. Chemistry12.2%
    3. Computer Science11.0%
    4. Materials Science00.7%
    5. Environmental Science00.2%
    6. Physics and Astronomy00.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 3.86× its world share, 4 worksBiochemistry, Geneti…Immunology and Microbiology: 13.89× its world share, 3 worksImmunology and Micro…Neuroscience: 0.18× its world share, 0 worksNeuroscienceChemistry: 3.30× its world share, 1 worksChemistryComputer Science: 0.22× its world share, 0 worksComputer ScienceEnvironmental Science: 0.13× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.49× its world share, 0 worksMaterials SciencePhysics and Astronomy: 0.04× its world share, 0 worksPhysics and AstronomyHealth Professions: 0.22× its world share, 0 worksHealth ProfessionsMedicine: 2.86× its world share, 11 worksMedicineVeterinary: 1.46× its world share, 0 worksVeterinary1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 13.9×. Every wedge is a field page.

All 11 fields, with their numbers
  1. Immunology and Microbiology13.89×3 works
  2. Biochemistry, Genetics and Molecular Biology3.86×4 works
  3. Chemistry3.30×1 works
  4. Medicine2.86×11 works
  5. Veterinary1.46×0 works
  6. Materials Science0.49×0 works
  7. Computer Science0.22×0 works
  8. Health Professions0.22×0 works
  9. Neuroscience0.18×0 works
  10. Environmental Science0.13×0 works
  11. Physics and Astronomy0.04×0 works

Who are the top researchers at Mersana Therapeutics (United States)?

Ranked on the quality score, Donald Alan Bergstrom, Marc Isaac Damelin and Timothy B. Lowinger lead among researchers whose main affiliation is Mersana Therapeutics (United States).

  1. 1 Donald Alan Bergstrom United States · #205,677 worldwide 3.2k citations · 248 works
  2. 2 Marc Isaac Damelin United States · #274,167 worldwide 2.8k citations · 195 works
  3. 3 Timothy B. Lowinger United States · #300,214 worldwide 3.9k citations · 211 works
  4. 4 Raghida A. Bukhalid United States · #314,766 worldwide 1.9k citations · 68 works
  5. 5 Rebecca E. Mosher United States · #324,995 worldwide 2.4k citations · 123 works
  6. 6 Michael J. DeVit United States · #325,583 worldwide 4.2k citations · 39 works
  7. 7 Laura L. Poling United States · #460,852 worldwide 1.9k citations · 60 works
  8. 8 LiuLiang Qin United States · #464,145 worldwide 2.3k citations · 152 works
  9. 9 Elena Ter‐Ovanesyan United States · #470,054 worldwide 489 citations · 104 works
  10. 10 Chen‐Ni Chin United States · #599,022 worldwide 2.1k citations · 38 works
All ranked researchers at Mersana Therapeutics (United States)

What are the most cited papers from Mersana Therapeutics (United States)?

The most cited paper from Mersana Therapeutics (United States) is "Single-vector inducible lentiviral RNAi system for oncology target validation" (Dmitri Wiederschain, W Nicolson Susan, Lin Chen et al., 2009), with 469 citations. Next come "Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial" (241) and "Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design" (137).

Most cited papers
#PaperReleasedCitations
1 Single-vector inducible lentiviral RNAi system for oncology target validation Dmitri Wiederschain, W Nicolson Susan, Lin Chen et al. · Cell Cycle Open access Feb 2009 469
2 Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial Ingo K. Mellinghoff, Min Lu, Patrick Yung Wen et al. · Nature Medicine Open access 23 Feb 2023 241
3 Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design Pamela A. Trail, Gene M. Dubowchik, Timothy B. Lowinger · Pharmacology & Therapeutics 27 Jul 2017 137
4 Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials Joan B. Mannick, Grace Sock Leng Teo, Bernardo Patti et al. · The Lancet Healthy Longevity Open access May 2021 122
5 A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy Alexander V. Yurkovetskiy, Mao Yin, Natalya D. Bodyak et al. · Cancer Research 26 Jun 2015 105
All 80 most cited papers, with filters and sorting

Which keywords describe research at Mersana Therapeutics (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Glycosylation, Monoclonal Antibodies, Therapeutic Antibodies, Antibody Engineering, Fc Receptors, Breast Cancer and Metastatic.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Chemotherapy15▲ 32×7 topics
  2. Glycosylation12▲ 85×2 topics
  3. Monoclonal Antibodies12▲ 129×3 topics
  4. Therapeutic Antibodies12▲ 144×2 topics
  5. Antibody Engineering12▲ 178×1 topic
  6. Fc Receptors12▲ 178×1 topic
  7. Breast Cancer11▲ 58×3 topics
  8. Metastatic11▲ 252×2 topics
  9. HER210▲ 521×1 topic
  10. Trastuzumab10▲ 369×1 topic
  11. Immunotherapy8▲ 19×8 topics
  12. PET Imaging7▲ 47×2 topics
  13. Targeted Therapy6▲ 45×4 topics
  14. Radioimmunotherapy4▲ 168×1 topic
  15. Radiopharmaceuticals4▲ 168×1 topic
  16. Metastatic Breast Cancer4▲ 99×2 topics
  17. Tumor Regression4▲ 74×2 topics
  18. Cancer Therapy4▲ 10×6 topics
  19. Quality of Life4▲ 4.8×3 topics
  20. Tumor Microenvironment4▲ 18×7 topics
  21. Chemotherapy-Induced Peripheral Neuropathy4▲ 123×1 topic
  22. Neurotoxicity4▲ 34×2 topics
  23. Taxanes4▲ 123×1 topic
  24. Innate Immunity4▲ 17×3 topics
  25. Tumor Targeting4▲ 45×3 topics
  26. Gene Therapy4▲ 21×3 topics
  27. Pattern Recognition Receptors4▲ 37×2 topics
  28. Interferon Signaling3▲ 151×1 topic
  29. Viral Infection3▲ 67×1 topic
  30. Clinical Trials3▲ 7.0×4 topics
  31. Arginine Deprivation2▲ 86×1 topic
  32. Bacterial Therapy2▲ 86×1 topic
  33. Cancer Immunotherapy2▲ 26×2 topics
  34. Angiogenesis2▲ 8.5×2 topics
  35. Fibroblast Activation Protein2▲ 67×1 topic
  36. Immunosuppression2▲ 30×1 topic
  37. Metastasis2▲ 10×4 topics
  38. Biomarkers2▲ 5.4×2 topics
  39. CAR T Cells2▲ 61×1 topic
  40. Chimeric Antigen Receptor2▲ 61×1 topic

Which research topics does Mersana Therapeutics (United States) publish most on?

By volume in 2022-now: Monoclonal and Polyclonal Antibodies Research, HER2/EGFR in Cancer Research, interferon and immune responses and Peptidase Inhibition and Analysis.

  1. 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
  2. 2 HER2/EGFR in Cancer Research Oncology 2 works
  3. 3 interferon and immune responses Immunology 2 works
  4. 4 Peptidase Inhibition and Analysis Oncology 1 works
  5. 5 Cancer Research and Treatments Biotechnology 1 works
  6. 6 Ovarian cancer diagnosis and treatment Reproductive Medicine 1 works
  7. 7 Neuroblastoma Research and Treatments Neurology 1 works
  8. 8 Virus-based gene therapy research Genetics 1 works
  9. 9 Cancer Treatment and Pharmacology Oncology 0 works
  10. 10 Lung Cancer Research Studies Oncology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available26.8%not open73.2%

World: 40% of research is openly available.

with international co-authors7.8%domestic only92.2%

World: 18% is written across borders.

How has Mersana Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 20% lower than in 2018-2021.

still counting2010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Mersana Therapeutics (United States) as a percentage of every work published that year, 0.000090% in 2024.

still counting0.00010%0.00020%Mersana Therapeutics (United States)0.000052% in 202520102020

Fractional works of Mersana Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Cambridge

All research institutions in Cambridge

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Mersana Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.